99 related articles for article (PubMed ID: 23856074)
1. Oral administration of a gemini vitamin D analog, a synthetic triterpenoid and the combination prevents mammary tumorigenesis driven by ErbB2 overexpression.
So JY; Wahler JE; Yoon T; Smolarek AK; Lin Y; Shih WJ; Maehr H; Uskokovic M; Liby KT; Sporn MB; Suh N
Cancer Prev Res (Phila); 2013 Sep; 6(9):959-70. PubMed ID: 23856074
[TBL] [Abstract][Full Text] [Related]
2. USP22 overexpression fails to augment tumor formation in MMTV-ERBB2 mice but loss of function impacts MMTV promoter activity.
Kuang X; Salinger A; Benavides F; Muller WJ; Dent SYR; Koutelou E
PLoS One; 2024; 19(1):e0290837. PubMed ID: 38236941
[TBL] [Abstract][Full Text] [Related]
3. MDA-7/IL-24 functions as a tumor suppressor gene in vivo in transgenic mouse models of breast cancer.
Menezes ME; Shen XN; Das SK; Emdad L; Guo C; Yuan F; Li YJ; Archer MC; Zacksenhaus E; Windle JJ; Subler MA; Ben-David Y; Sarkar D; Wang XY; Fisher PB
Oncotarget; 2015 Nov; 6(35):36928-42. PubMed ID: 26474456
[TBL] [Abstract][Full Text] [Related]
4. Caloric restriction inhibits mammary tumorigenesis in MMTV-ErbB2 transgenic mice through the suppression of ER and ErbB2 pathways and inhibition of epithelial cell stemness in premalignant mammary tissues.
Ma Z; Parris AB; Howard EW; Shi Y; Yang S; Jiang Y; Kong L; Yang X
Carcinogenesis; 2018 Oct; 39(10):1264-1273. PubMed ID: 30107476
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of miR-489 derails mammary hierarchy structure and inhibits HER2/neu-induced tumorigenesis.
Patel Y; Soni M; Awgulewitsch A; Kern MJ; Liu S; Shah N; Singh UP; Chen H
Oncogene; 2019 Jan; 38(3):445-453. PubMed ID: 30104710
[TBL] [Abstract][Full Text] [Related]
6. ADAMTS18 deficiency associates extracellular matrix dysfunction with a higher risk of HER2-positive mammary tumorigenesis and metastasis.
Nie J; Dang S; Zhu R; Lu T; Zhang W
Breast Cancer Res; 2024 Jan; 26(1):19. PubMed ID: 38287441
[TBL] [Abstract][Full Text] [Related]
7. In MMTV-Her-2/neu transgenic mammary tumors the absence of caveolin-1-/- alters PTEN and NHERF1 but not β-catenin expression.
Cuello-Carrión FD; Cayado-Gutiérrez N; Natoli AL; Restall C; Anderson RL; Nadin S; Alvarez-Olmedo D; Castro GN; Gago FE; Fanelli MA; Ciocca DR
Cell Stress Chaperones; 2013 Sep; 18(5):559-67. PubMed ID: 23397229
[TBL] [Abstract][Full Text] [Related]
8. Hormonally up-regulated neu-associated kinase: A novel target for breast cancer progression.
Zambrano JN; Neely BA; Yeh ES
Pharmacol Res; 2017 May; 119():188-194. PubMed ID: 28189783
[TBL] [Abstract][Full Text] [Related]
9. ErbB2 is required for ductal morphogenesis of the mammary gland.
Jackson-Fisher AJ; Bellinger G; Ramabhadran R; Morris JK; Lee KF; Stern DF
Proc Natl Acad Sci U S A; 2004 Dec; 101(49):17138-43. PubMed ID: 15569931
[TBL] [Abstract][Full Text] [Related]
10. Elevated expression of wildtype RhoC promotes ErbB2- and Pik3ca-induced mammary tumor formation.
Raghuram N; Temel EI; Kawamata T; Kozma KJ; Loch AJ; Wang W; Adams JR; Muller WJ; Egan SE
Breast Cancer Res; 2024 May; 26(1):86. PubMed ID: 38807216
[TBL] [Abstract][Full Text] [Related]
11. Hunk is required for HER2/neu-induced mammary tumorigenesis.
Yeh ES; Yang TW; Jung JJ; Gardner HP; Cardiff RD; Chodosh LA
J Clin Invest; 2011 Mar; 121(3):866-79. PubMed ID: 21393859
[TBL] [Abstract][Full Text] [Related]
12. Hormone-induced protection of mammary tumorigenesis in genetically engineered mouse models.
Rajkumar L; Kittrell FS; Guzman RC; Brown PH; Nandi S; Medina D
Breast Cancer Res; 2007; 9(1):R12. PubMed ID: 17257424
[TBL] [Abstract][Full Text] [Related]
13. Proteomic characterization of Her2/neu-overexpressing breast cancer cells.
Chen H; Pimienta G; Gu Y; Sun X; Hu J; Kim MS; Chaerkady R; Gucek M; Cole RN; Sukumar S; Pandey A
Proteomics; 2010 Nov; 10(21):3800-10. PubMed ID: 20960451
[TBL] [Abstract][Full Text] [Related]
14. Rab11-FIP1C Is a Critical Negative Regulator in ErbB2-Mediated Mammary Tumor Progression.
Boulay PL; Mitchell L; Turpin J; Huot-Marchand JÉ; Lavoie C; Sanguin-Gendreau V; Jones L; Mitra S; Livingstone JM; Campbell S; Hallett M; Mills GB; Park M; Chodosh L; Strathdee D; Norman JC; Muller WJ
Cancer Res; 2016 May; 76(9):2662-74. PubMed ID: 26933086
[TBL] [Abstract][Full Text] [Related]
15. A multiantigen vaccine targeting neu, IGFBP-2, and IGF-IR prevents tumor progression in mice with preinvasive breast disease.
Disis ML; Gad E; Herendeen DR; Lai VP; Park KH; Cecil DL; O'Meara MM; Treuting PM; Lubet RA
Cancer Prev Res (Phila); 2013 Dec; 6(12):1273-82. PubMed ID: 24154719
[TBL] [Abstract][Full Text] [Related]
16. Peptides for Dual Targeting of ErbB1 and ErbB2: Blocking EGFR Cell Signaling Transduction Pathways for Cancer Chemotherapy.
Patnaik SK; Swaroop AK; Nagarjuna P; Nanjan MJ; Chandrasekar MJN
Curr Mol Pharmacol; 2024; 17(1):e240223214012. PubMed ID: 36843255
[TBL] [Abstract][Full Text] [Related]
17. Clinical applications of mouse models for breast cancer engaging HER2/neu.
Fry EA; Taneja P; Inoue K
Integr Cancer Sci Ther; 2016; 3(5):593-603. PubMed ID: 28133539
[TBL] [Abstract][Full Text] [Related]
18. Targeting collagen XVIII improves the efficiency of ErbB inhibitors in breast cancer models.
Devarajan R; Izzi V; Peltoketo H; Rask G; Kauppila S; Väisänen MR; Ruotsalainen H; Martínez-Nieto G; Karppinen SM; Väisänen T; Kaur I; Koivunen J; Sasaki T; Winqvist R; Manninen A; Wärnberg F; Sund M; Pihlajaniemi T; Heljasvaara R
J Clin Invest; 2023 Sep; 133(18):. PubMed ID: 37498672
[TBL] [Abstract][Full Text] [Related]
19. Paternal Combined Botanicals Contribute to the Prevention of Estrogen Receptor-Negative Mammary Cancer in Transgenic Mice.
Li S; Wu H; Chen M; Tollefsbol TO
J Nutr; 2023 Jul; 153(7):1959-1973. PubMed ID: 37146973
[TBL] [Abstract][Full Text] [Related]
20. NEDD9 Overexpression Causes Hyperproliferation of Luminal Cells and Cooperates with HER2 Oncogene in Tumor Initiation: A Novel Prognostic Marker in Breast Cancer.
Purazo ML; Ice RJ; Shimpi R; Hoenerhoff M; Pugacheva EN
Cancers (Basel); 2023 Feb; 15(4):. PubMed ID: 36831460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
